In this modern era of cancer treatment, monoclonal antibodies directed against PD-1 or PD-L1 can result in promising tumor responses, and many of these antibodies have been approved by the FDA for a wide spectrum of advanced/metastatic cancers. This evidence concerns the gene CD274 and neoplasm.